Compare Quest Diagnostics Inc (DGX) vs iShares Gold Trust (IAU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares Gold Trust — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while iShares Gold Trust trades at $78.87 (market cap $61.51B). The key difference: iShares Gold Trust is far larger — about 2.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares Gold Trust for 49 Days on average.
| DGX | IAU | |
|---|---|---|
Market Cap | $25.48B | $61.51B |
Volume | 941,866 | 3,206,729 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $247.45 | $101.57 |
52-Week Low | $173.49 | $74.21 |
Typical Hold Time | 56 Days | 49 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
IAU stock trades at $77.66 with a modest 0.78% daily gain amid bearish technical signals. The stock faces significant selling pressure with moving averages indicating a strong downtrend while oscillators remain neutral. Recent news highlights gold's sensitivity to interest rate expectations and Treasury yield movements, with mixed sentiment from financial media regarding near-term prospects.
The outlook remains cautious with technical indicators favoring sellers, though oversold conditions could present tactical opportunities. Key risks include persistent rate hike expectations and dollar strength, while institutional positioning suggests defensive sentiment prevails in the current macroeconomic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →
